Delving into the Latest Updates on EDP-1503 with Synapse

Overview

Basic Info

Drug Type

Live biotherapeutic products

Synonyms

Target-

Mechanism

Bacteria replacements, Microbiome modulators

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Melanoma, Cutaneous MalignantMelanoma

Inactive Indication

Bladder CancerColorectal CancerEsophageal Carcinoma+ [8]

Originator Organization

The University of Chicago

Active Organization

Merck Sharp & Dohme Corp.

The University of Chicago

Inactive Organization

Evelo Biosciences, Inc.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study is being done to determine if orally administered EDP1503 will enhance the response to standard immunotherapy treatment (pembrolizumab) in participants with advanced melanoma.
The study will involve initial administration of EDP1503 for a run-in period (2 weeks) followed by administration of both EDP1503 (twice daily) and pembrolizumab (every 3 weeks).
Mandatory biopsies are required before starting study treatment and after 2 weeks of EDP1503 dosing.

Start Date02 Oct 2018

Sponsor / Collaborator

The University of Chicago

[+2]

100 Clinical Results associated with EDP-1503

Login to view more data

100 Translational Medicine associated with EDP-1503

Login to view more data

100 Patents (Medical) associated with EDP-1503

Login to view more data

100 Deals associated with EDP-1503

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 2	CA	Evelo Biosciences, Inc.	19 Dec 2018
Bladder Cancer	Phase 2	US	Evelo Biosciences, Inc.	19 Dec 2018
Colorectal Cancer	Phase 2	CA	Evelo Biosciences, Inc.	19 Dec 2018
Colorectal Cancer	Phase 2	US	Evelo Biosciences, Inc.	19 Dec 2018
Renal Cell Carcinoma	Phase 2	CA	Evelo Biosciences, Inc.	19 Dec 2018
Renal Cell Carcinoma	Phase 2	US	Evelo Biosciences, Inc.	19 Dec 2018
Triple Negative Breast Cancer	Phase 2	US	Evelo Biosciences, Inc.	19 Dec 2018
Triple Negative Breast Cancer	Phase 2	CA	Evelo Biosciences, Inc.	19 Dec 2018
Melanoma, Cutaneous Malignant	Phase 2	US	Merck Sharp & Dohme Corp.	02 Oct 2018
Melanoma	Phase 2	-	The University of Chicago	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03775850 (EDP1503-101, AACR2021) Manual	Phase 1/2	Triple Negative Breast Cancer	15	EDP1503+pembrolizumab	(iqjnpmqhzk) = mkkbumamqm ondnrmitdv (nzbuvidrmw ) View more	Positive	15 Feb 2021